Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).
MB-106 is an novel CD20 chimeric antigen receptor (CAR) T-cell therapy. A study evaluating its efficacy and safety of MB-106 was recently presented during the Transplantation & Cellular Therapy Meetings.
According to Shadman, CD20 CAR T-cell therapy was explored similarly to the other FDA approved CAR T cells.
0:08 | Patients with relapsed refractory CD20 positive B-cell malignancies were eligible including CLL. Each histology had a specific inclusion and exclusion criteria for large cell lymphoma versus CLL versus follicular lymphoma we have had a specific eligibility criteria but basically they had to be in the relapsed refractory setting as part of the study the CD 20 expression needed to be confirmed. Otherwise, the method was very similar to two other FDA approved autologous CAR T products.
0:47 | Patients would after enrollment they would go undergo look of phrases and in the meantime, while the cells were being manufactured the some patients needed bridging therapy. When cells were ready, they received chemo using to fludarabine and cyclophosphamide. And after 2 days of rest, they receive their cell dose. We had disease assessment at day 28 including a PET scan and bone marrow biopsy, if necessary.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More